Page last updated: 2024-10-26

fenfluramine and Diabetes Mellitus, Type 2

fenfluramine has been researched along with Diabetes Mellitus, Type 2 in 54 studies

Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

ExcerptRelevanceReference
"3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity."9.08Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996)
"To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk."9.07Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993)
"We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance."7.68Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993)
"In the patients with obesity and NIDDM, the fasting and postprandial blood glucose and glycosylated haemoglobin were also highly significantly reduced."6.68[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997)
"3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity."5.08Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996)
"Dexfenfluramine aids weight loss and improves glycemic control in obese Chinese NIDDM patients over a 3- to 6-month period."5.08Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. ( Chan, JC; Chow, CC; Cockram, CS; Ko, GT; Tsang, LW; Yeung, VT, 1997)
"To assess the effect of dexfenfluramine on weight loss, diabetic control and blood lipids in type II diabetics over a three-month period."5.07Dexfenfluramine in type II diabetes: effect on weight and diabetes control. ( Davis, TM; Findlater, P; Stein, GR; Stewart, GO, 1993)
"To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk."5.07Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993)
"Dexfenfluramine has been shown to promote weight loss in overweight people."5.07The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. ( Molyneaux, LM; Overland, JE; Willey, KA; Yue, DK, 1992)
" Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals."4.78[Mode of action of benfluorex. Recent data]. ( Brindley, DN, 1992)
"We have examined the effect of chronic (21 days) oral administration of the serotoninergic anorectic drug d-fenfluramine (5 mg/kg) in a rat model of non-insulin-dependent diabetes (without obesity), as induced by injection of a low dose (45 mg/kg) of streptozotocin at 6 weeks, and characterized by marked hyperglycaemia and hepatic and peripheral insulin resistance."3.69d-Fenfluramine improves hepatic insulin action in streptozotocin-diabetic rats. ( Bailbé, D; Picarel-Blanchot, F; Portha, B, 1994)
"The authors have evaluated the efficacy of d-fenfluramine, a serotoninergic anorectic drug, in 42 obese patients with non-insulin-dependent diabetes mellitus (NIDDM) who not very responded only to the hypocaloric diet or associated therapy with oral hypoglycemic agents."3.69[The treatment of the obese non-insulin-dependent patient with d-fenfluramine]. ( Coco, MP; Daniele, E, 1996)
"To validate a variation of a well-established magnetic resonance imaging (MRI) technique to detect liver fat and use it to monitor liver fat changes after treatment with dexfenfluramine in men with non-insulin dependent diabetes mellitus (NIDDM)."3.69Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. ( Clark, ML; Hockaday, TD; Marks, SJ; Moore, NR; Pointon, JJ; Ryley, NG; Strauss, BJ, 1997)
"We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance."3.68Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993)
"Treatment with benfluorex was well tolerated; 39% of these patients reported one or more emergent adverse events (compared to 38% on placebo and 43% on metformin) and only two patients suffered a treatment-related, serious adverse event."2.71Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. ( Del Prato, S; Erkelens, DW; Leutenegger, M, 2003)
"Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin."2.69Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998)
"Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective."2.69Pharmacologic induction of weight loss to treat type 2 diabetes. ( Bantle, JP; Kwong, CA; Raatz, SK; Redmon, JB; Swanson, JE; Thomas, W, 1999)
"Dexfenfluramine was most effective in the short term, behavioural therapy useful long term but only in those who remained within the group; home visits offered no advantage."2.68The comparison of four weight reduction strategies aimed at overweight diabetic patients. ( Jung, RT; Leese, GP; Manning, RM; Newton, RW, 1995)
"In the patients with obesity and NIDDM, the fasting and postprandial blood glucose and glycosylated haemoglobin were also highly significantly reduced."2.68[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997)
"Benfluorex is a hypolipidaemic agent with biguanide-like properties."2.67Mechanism(s) of the blood glucose lowering action of benfluorex. ( Da Tos, V; De Biasi, L; Del Prato, S; Dorella, M; Marescotti, MC; Riccio, A; Tiengo, A; Vigili de Kreutzenberg, S, 1993)
"Benfluorex hydrochloride has known lipid- and glucose-lowering effects."2.67Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993)
"Benfluorex is a hypolipidemic agent with biguanide-like properties."2.67[Mechanisms of hypoglycemic action of benfluorex]. ( Da Tos, V; Del Prato, S; Dorella, M; Riccio, A; Vigili de Kreutzenberg, S, 1992)
"Benfluorex has been reported to decrease blood glucose in different dismetabolic conditions, particularly in noninsulin-dependent diabetic (NIDD) patients, but the mechanism of this effect is poorly known."2.67Benfluorex and blood glucose control in non insulin-dependent diabetic patients. ( Boine, L; Cavallo-Perin, P; Cobelli, C; Estivi, P; Galletti, R; Pacini, G; Pagano, G, 1991)
"Insulin resistance is one of the cardinal pathophysiological components of the metabolic syndrome, type 2 diabetes, and frequently co-exists with essential hypertension."2.40Insulin resistance: site of the primary defect or how the current and the emerging therapies work. ( Caro, JF; Kolaczynski, JW, 1998)
"The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes."2.40[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. ( Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N, 1999)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19905 (9.26)18.7374
1990's38 (70.37)18.2507
2000's5 (9.26)29.6817
2010's5 (9.26)24.3611
2020's1 (1.85)2.80

Authors

AuthorsStudies
Göldner, V1
Karst, U1
Moulin, P3
André, M2
Alawi, H2
Dos Santos, LC2
Khalid, AK2
Koev, D2
Moore, R2
Serban, V2
Picandet, B3
Francillard, M2
Benkimoun, P1
Nau, JY1
Vincent, L1
Guardiola, B1
Tsouderos, Y1
Canet, E1
Derumeaux, G1
Ernande, L1
Serusclat, A1
Servan, E1
Bruckert, E1
Rousset, H1
Senn, S1
Van Gaal, L1
Gavini, F1
Watson, R1
Del Prato, S3
Erkelens, DW3
Leutenegger, M2
Boulé, NG1
Chaput, JP1
Doucet, E1
Richard, D1
Després, JP1
Bouchard, C1
Tremblay, A1
Verdy, M4
Charbonneau, L1
Verdy, I3
Belanger, R1
Bolte, E1
Chiasson, JL3
Hamet, P2
Manning, RM1
Jung, RT1
Leese, GP1
Newton, RW1
Picarel-Blanchot, F1
Bailbé, D3
Portha, B3
Greco, AV1
Mingrone, G1
Capristo, E1
De Gaetano, A1
Ghirlanda, G1
Castagneto, M1
Proietto, J1
Thorburn, AW1
Fabris, S1
Harrison, LC1
Walsh, JP1
Davis, TM2
Stewart, GO2
Stein, GR2
Findlater, P2
Riccio, A2
Vigili de Kreutzenberg, S2
Dorella, M2
Da Tos, V2
De Biasi, L1
Marescotti, MC1
Tiengo, A1
De Feo, P1
Lavielle, R1
De Gregoris, P1
Bolli, GB1
Bianchi, R2
Bongers, V2
Bravenboer, B2
Brindley, DN2
Serradas, P2
Blondel, O2
Picarel, F1
Storlien, LH1
Pan, DA1
Kusunoki, M1
Cooney, GJ1
Daniele, E1
Coco, MP1
Marks, SJ2
Moore, NR2
Clark, ML2
Strauss, BJ2
Hockaday, TD2
Pontiroli, AE1
Pacchioni, M1
Piatti, PM1
Cassisa, C1
Camisasca, R1
Pozza, G1
Ryley, NG1
Pointon, JJ1
Chow, CC1
Ko, GT1
Tsang, LW1
Yeung, VT1
Chan, JC1
Cockram, CS1
Enzi, G1
DeMeo, MT1
Mobarhan, S1
Mikolaitis, S1
Kazi, N1
Ravel, D1
Redmon, B1
Raatz, S1
Bantle, JP3
Marinella, MA1
Berrettoni, BA1
Bauduceau, B1
Brun, JM2
Guillon-Metz, F1
Martin, C1
Nicolino-Peltier, C1
Richard, JL1
Vannereau, D1
Drain, P1
Kolaczynski, JW1
Caro, JF1
Redmon, JB2
Raatz, SK2
Kwong, CA2
Swanson, JE2
Thomas, W1
Brogard, JM1
Neyrolles, N1
Andres, E1
Blicklé, JF1
Rothman, RB1
Willey, KA1
Molyneaux, LM1
Overland, JE1
Yue, DK1
Balabolkin, MI1
Novikova, OM1
Levitskaia, ZI1
Meinders, AE1
Scheen, AJ1
Paolisso, G1
Salvatore, T1
Lefèbvre, PJ1
Cavallo-Perin, P1
Estivi, P1
Boine, L1
Galletti, R1
Pacini, G1
Cobelli, C1
Pagano, G1
Pestell, RG1
Crock, PA1
Ward, GM1
Alford, FP1
Best, JD1
Beauchamp, Y1
Bissonnette, J1
Farah-Lajoie, C1
Graham, S1
Guay, JP1
Kingsley, N1
Perrier, A1
Rochon, JL1
Treymann, D1

Reviews

8 reviews available for fenfluramine and Diabetes Mellitus, Type 2

ArticleYear
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
    Diabetes/metabolism reviews, 1993, Volume: 9 Suppl 1

    Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl

1993
Effects of benfluorex on in vivo patterns of insulin resistance induced by diets rich in fat or fructose.
    Diabetes/metabolism reviews, 1993, Volume: 9 Suppl 1

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Dietary Fa

1993
[Benfluorex (Mediator) and non-insulin-dependent diabetes].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1997

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hypolipidemic Agents; Insul

1997
[Benfluorex (Mediator): non-insulin-dependent diabetes and hypertriglyceridemia].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1998

    Topics: Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hypertriglyceridemia

1998
Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
    Journal of basic and clinical physiology and pharmacology, 1998, Volume: 9, Issue:2-4

    Topics: Adipose Tissue; Appetite Depressants; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypog

1998
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
    La Revue de medecine interne, 1999, Volume: 20 Suppl 3

    Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine

1999
[Mode of action of benfluorex. Recent data].
    Presse medicale (Paris, France : 1983), 1992, Sep-09, Volume: 21, Issue:28

    Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids; Female; Fenflu

1992
Very low calorie diets and recently developed anti-obesity drugs for treating overweight in non-insulin-dependent diabetics.
    The Netherlands journal of medicine, 1990, Volume: 37, Issue:3-4

    Topics: Adrenergic beta-Agonists; Diabetes Mellitus, Type 2; Diet, Reducing; Fenfluramine; Fluoxetine; Human

1990

Trials

28 trials available for fenfluramine and Diabetes Mellitus, Type 2

ArticleYear
Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18 to 34-week, open-label, extension period.
    Diabetes & metabolism, 2009, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenf

2009
Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Aged; Diabetes Mellitus, Type 2; Echocardiography; Female; Fenfluramine; Glycated Hemoglobin; Heart

2012
Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.
    Acta diabetologica, 2003, Volume: 40, Issue:1

    Topics: Appetite Depressants; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female

2003
Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study.
    Diabetes care, 2006, Volume: 29, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fema

2006
Glucose homeostasis predicts weight gain: prospective and clinical evidence.
    Diabetes/metabolism research and reviews, 2008, Volume: 24, Issue:2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fenfluramine; Glucose Tolerance Test;

2008
Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.
    International journal of obesity, 1983, Volume: 7, Issue:4

    Topics: Aged; Appetite Depressants; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Meth

1983
The comparison of four weight reduction strategies aimed at overweight diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:5

    Topics: Adolescent; Adult; Aged; Behavior Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Me

1995
Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus.
    Metabolism: clinical and experimental, 1995, Volume: 44, Issue:2 Suppl 2

    Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Female; Fenfluramine; Huma

1995
Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus.
    Diabetes research and clinical practice, 1994, Volume: 23, Issue:2

    Topics: Adult; Aged; Blood Glucose; Central Nervous System; Diabetes Mellitus, Type 2; Female; Fenfluramine;

1994
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
    The Medical journal of Australia, 1994, Apr-18, Volume: 160, Issue:8

    Topics: Diabetes Mellitus, Type 2; Fenfluramine; Glycated Hemoglobin; Humans; Weight Loss

1994
Mechanism(s) of the blood glucose lowering action of benfluorex.
    Diabetes/metabolism reviews, 1993, Volume: 9 Suppl 1

    Topics: Appetite Depressants; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diet, Diabetic; Female;

1993
Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus.
    Diabetes/metabolism reviews, 1993, Volume: 9 Suppl 1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Fenfluram

1993
Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
    Diabetes/metabolism reviews, 1993, Volume: 9 Suppl 1

    Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method;

1993
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
    The Medical journal of Australia, 1993, Feb-01, Volume: 158, Issue:3

    Topics: Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2;

1993
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
    Diabetes care, 1993, Volume: 16, Issue:4

    Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol;

1993
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:10

    Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel

1996
Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Diabetes care, 1997, Volume: 20, Issue:7

    Topics: Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; China; Diabetes Mellitu

1997
[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Terapevticheskii arkhiv, 1997, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Appetite Depressants; Diabetes Mellitus; Diabetes Mel

1997
Added benfluorex in obese insulin-requiring type 2 diabetes.
    Diabetes & metabolism, 1998, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus

1998
Pharmacologic induction of weight loss to treat type 2 diabetes.
    Diabetes care, 1999, Volume: 22, Issue:6

    Topics: Appetite Depressants; Behavior Therapy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetes M

1999
Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.
    The American journal of cardiology, 2000, Apr-01, Volume: 85, Issue:7

    Topics: Administration, Oral; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fem

2000
[Mechanisms of hypoglycemic action of benfluorex].
    Presse medicale (Paris, France : 1983), 1992, Sep-09, Volume: 21, Issue:28

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Fenfluramine; Fructosamine; Glycated He

1992
[Antidiabetic efficacy of benfluorex. Clinical data].
    Presse medicale (Paris, France : 1983), 1992, Sep-09, Volume: 21, Issue:28

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypolipidemic A

1992
The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 1992, Volume: 9, Issue:4

    Topics: Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2

1992
Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
    Diabetes care, 1991, Volume: 14, Issue:4

    Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Me

1991
Benfluorex and blood glucose control in non insulin-dependent diabetic patients.
    Journal of endocrinological investigation, 1991, Volume: 14, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenfluramine; Humans; Hypolip

1991
Fenfluramine increases insulin action in patients with NIDDM.
    Diabetes care, 1989, Volume: 12, Issue:4

    Topics: Adult; Aged; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fem

1989
Hypoglycemic effect of fenfluramine in insulin-treated diabetics.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1986, Volume: 9, Issue:1

    Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus,

1986

Other Studies

18 other studies available for fenfluramine and Diabetes Mellitus, Type 2

ArticleYear
Benfluorex metabolism complemented by electrochemistry-mass spectrometry.
    Journal of pharmaceutical and biomedical analysis, 2023, Oct-25, Volume: 235

    Topics: Diabetes Mellitus, Type 2; Electrochemistry; Fenfluramine; Humans; Norfenfluramine; Tandem Mass Spec

2023
French doctors demand to know why drug stayed on the market for so long.
    BMJ (Clinical research ed.), 2010, Dec-03, Volume: 341

    Topics: Attitude of Health Personnel; Diabetes Mellitus, Type 2; Fenfluramine; France; Humans; Hypoglycemic

2010
[What were the indications for the Mediator in 1979?].
    Revue medicale suisse, 2011, Feb-09, Volume: 7, Issue:281

    Topics: Anxiety; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; France; Heart Valve Diseases

2011
Mediator: who's to blame?
    Lancet (London, England), 2011, Jun-11, Volume: 377, Issue:9782

    Topics: Appetite Depressants; Diabetes Mellitus, Type 2; Drug Industry; Fenfluramine; France; Glycated Hemog

2011
European legislators tighten rules on drug safety.
    BMJ (Clinical research ed.), 2012, Sep-18, Volume: 345

    Topics: Adverse Drug Reaction Reporting Systems; Appetite Depressants; Diabetes Mellitus, Type 2; Europe; Fe

2012
[Speed of action of fenfluramine on blood glucose levels].
    L'union medicale du Canada, 1983, Volume: 112, Issue:10

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Middle Aged

1983
d-Fenfluramine improves hepatic insulin action in streptozotocin-diabetic rats.
    European journal of pharmacology, 1994, Oct-24, Volume: 264, Issue:2

    Topics: Administration, Oral; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Experimental;

1994
Insulin resistance, hyperinsulinemia and diabetes--contribution of benfluorex. Prague, 11 September 1992. Symposium proceedings.
    Diabetes/metabolism reviews, 1993, Volume: 9 Suppl 1

    Topics: Animals; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperinsulinism; Hypoglycemic Agents; Insu

1993
Effect of benfluorex on insulin secretion and insulin action in streptozotocin-diabetic rats.
    Diabetes/metabolism reviews, 1993, Volume: 9 Suppl 1

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fenfluramine; Gl

1993
Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats.
    Diabetes, 1993, Volume: 42, Issue:4

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Fenflura

1993
[The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
    La Clinica terapeutica, 1996, Volume: 147, Issue:4

    Topics: Adult; Aged; Appetite Depressants; Chronic Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dr

1996
Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.
    Obesity research, 1996, Volume: 4, Issue:1

    Topics: Adipose Tissue; Adult; Appetite Depressants; Body Composition; Body Constitution; Body Mass Index; C

1996
Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997, Volume: 21, Issue:4

    Topics: Adult; Biopsy; Confidence Intervals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Liver; Fema

1997
Three cases of comprehensive dietary therapy and pharmacotherapy of patients with complex obesity-related diseases.
    Nutrition reviews, 1997, Volume: 55, Issue:8

    Topics: Adult; Aged; Appetite Depressants; Diabetes Mellitus, Type 2; Diet, Reducing; Fatty Liver; Female; F

1997
Valvular heart disease associated with fenfluramine-phentermine.
    The New England journal of medicine, 1997, Dec-11, Volume: 337, Issue:24

    Topics: Appetite Depressants; Diabetes Mellitus, Type 2; Drug Combinations; Female; Fenfluramine; Heart Valv

1997
Digital necrosis associated with dexfenfluramine.
    The New England journal of medicine, 1997, Dec-11, Volume: 337, Issue:24

    Topics: Adult; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; Fingers; Humans; Male; Necrosi

1997
[Effects of ponderal on the state of carbohydrate metabolism and insulin secretion in type 2 diabetes mellitus].
    Sovetskaia meditsina, 1991, Issue:11

    Topics: Adult; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female;

1991
[Treatment of type II diabetes with fenfluramine. Usefulness in general practice].
    L'union medicale du Canada, 1986, Volume: 115, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Family Practice; Female; Fenfluramine; Humans; Male; Middle

1986
chemdatabank.com